Skip to content
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning episode artwork

Sep 17, 2025 5 min

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

from Conference Coverage

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

0:00 5:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Conference Coverage?

This episode is 5 minutes long.

When was this Conference Coverage episode published?

This episode was published on September 17, 2025.

Can I download this Conference Coverage episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.